AT-051/43421517 is a cytoprotective agent and apoptosis inhibitor that binds to human phosphoglycerate kinase 1 ( hPgk1 ). AT-051/43421517 protects cells from rotenone-induced cell death without inducing cell proliferation. AT-051/43421517 can be used for the research of parkinson’s disease [1].
In Vitro, AT-051/43421517 binds to purified human phosphoglycerate kinase 1 (hPgk1) with a ChemScore of 33.379, occupying the same binding site as terazosin and forming characteristic hydrophobic interactions with key hPgk1 residues[1]. AT-051/43421517 (10 μM; 48 h) protects PC12 cells from rotenone-induced cell death, increasing cell viability to 87.97% of control without inducing cell proliferation[1].
References:
[1]. Xia J, et al. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors. Molecules. 2017;22(6):1029. Published 2017 Jun 21.
In Vitro, AT-051/43421517 binds to purified human phosphoglycerate kinase 1 (hPgk1) with a ChemScore of 33.379, occupying the same binding site as terazosin and forming characteristic hydrophobic interactions with key hPgk1 residues[1]. AT-051/43421517 (10 μM; 48 h) protects PC12 cells from rotenone-induced cell death, increasing cell viability to 87.97% of control without inducing cell proliferation[1].
References:
[1]. Xia J, et al. Virtual Screening against Phosphoglycerate Kinase 1 in Quest of Novel Apoptosis Inhibitors. Molecules. 2017;22(6):1029. Published 2017 Jun 21.